2024-11-04 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a range of branded prescription pharmaceutical products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** ABBV (163.81%) has outperformed the S&P 500 (VOO) (131.78%) by **32.03%**. 
* **Relative Strength:**  The stock is currently at the 72.17th percentile of its historical relative performance against the S&P 500, indicating strong outperformance compared to the past.
* **Alpha & Beta Analysis:**
    * **Alpha:** AbbVie has generally outperformed the market, especially in 2017, 2020, and 2024. 
    * **Beta:**  The stock's beta has fluctuated over the years, indicating varying degrees of sensitivity to market movements.
* **Overall:** ABBV has consistently outperformed the S&P 500 in terms of cumulative returns, with a significant lead in recent years.  

**2. Recent Price Movement:**

* **Closing Price:**  $203.55 (Last-market: $203.56)
* **Moving Averages:**
    * 5-day: $197.61
    * 20-day: $192.70
    * 60-day: $194.07
* **Analysis:** ABBV is currently trading above its 5-day, 20-day, and 60-day moving averages, indicating a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 61.91 (Neutral)
* **PPO:** 0.85 (Bullish)
* **Delta_Previous_Relative_Divergence:** 11.54 (+) (Short-term upward trend)
* **Expected Return:** 1.5% (Long-term expected return exceeding S&P 500 by 1.5%)

**4. Recent Earnings and Outlook:**

* **EPS:** 
    * 2024-10-30: $3.00 (slightly exceeding expectations of $2.92)
    * 2024-07-25: $2.65 (slightly exceeding expectations of $2.57)
    * 2024-04-26: $2.31 (slightly exceeding expectations of $2.26)
    * 2024-02-02: $2.79 (slightly exceeding expectations of $2.76)
    * 2023-10-27: $2.95 (slightly exceeding expectations of $2.86)
* **Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters, demonstrating solid financial performance.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B | 66.74% |
| 2023-12-31 | $14.30B | 60.11% |
| 2023-09-30 | $13.93B | 53.44% |
| 2023-06-30 | $13.87B | 69.42% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |
| 2023-06-30 | $12.87B | 15.73% |

**Analysis:** ABBV has demonstrated strong revenue growth and consistent profitability. The company also maintains a healthy level of equity and a good return on equity.

**6. News and Recent Issues:**

* **Recent Earnings News:** AbbVie's latest earnings report, released on October 30th, 2024, showed a slight beat on EPS, which was positively received by the market. 
* **Analyst Opinions:** According to Finbold, analysts are generally positive about ABBV's performance and outlook, citing its strong revenue growth, strong pipeline, and focus on innovation.
* **Recent Market Outlook:** ABBV is viewed as a solid, established pharmaceutical company with a long track record of success. The recent positive earnings announcement and favorable analyst sentiment suggest a bullish outlook for the stock.

**7. Overall Analysis:**

ABBV is a strong, financially sound company with a solid track record of performance and a positive outlook. The stock has consistently outperformed the market and shows a bullish technical profile, suggesting potential for future growth. Its strong financial position, consistent earnings growth, and positive analyst sentiment make ABBV an attractive investment opportunity, especially for long-term investors seeking steady returns. 
